Analysts predict that Genocea Biosciences, Inc. (NASDAQ:GNCA) will announce ($0.38) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with estimates ranging from ($0.46) to ($0.30). Genocea Biosciences posted earnings per share of ($0.56) in the same quarter last year, which would indicate a positive year-over-year growth rate of 32.1%. The firm is expected to announce its next earnings report on Thursday, February 15th.
On average, analysts expect that Genocea Biosciences will report full year earnings of ($2.09) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($1.22) per share, with EPS estimates ranging from ($1.63) to ($0.80). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.08). During the same quarter in the prior year, the company earned ($0.45) earnings per share.
GNCA has been the topic of a number of analyst reports. Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. ValuEngine downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Monday, July 24th. Cowen and Company reiterated an “outperform” rating and set a $40.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Finally, Stifel Nicolaus downgraded Genocea Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $15.00 to $2.50 in a research report on Monday, September 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $7.62.
Hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in Genocea Biosciences during the second quarter worth $100,000. Ameriprise Financial Inc. increased its stake in Genocea Biosciences by 34.1% during the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 5,068 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in Genocea Biosciences during the second quarter worth $125,000. Rhumbline Advisers acquired a new stake in Genocea Biosciences during the second quarter worth $157,000. Finally, New York State Common Retirement Fund acquired a new stake in Genocea Biosciences during the second quarter worth $159,000. 57.53% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/11/19/zacks-analysts-expect-genocea-biosciences-inc-gnca-to-post-0-38-eps.html.
Genocea Biosciences (NASDAQ GNCA) traded up $0.03 on Tuesday, hitting $1.16. The stock had a trading volume of 147,468 shares, compared to its average volume of 584,697. Genocea Biosciences has a 52 week low of $1.03 and a 52 week high of $7.29. The company has a current ratio of 1.55, a quick ratio of 2.97 and a debt-to-equity ratio of 2.51.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.